Continue reading here:
Tag Archives: largest
Noblestitch Suture-Mediated PFO Closure Yields Zero Recurrent Strokes in the largest cohort with Four-Year Study presented at the TCT cardiology…
See the original post:
What is the largest organ in the body? Skin versus liver, explained. – USA TODAY
Your anatomy operates like a machine, it's success hinging on the work of over 70 organs, each with a unique function. From the heart's blood pumping ability, to the liver's filtering power, each component of the human ecosystem forms anintegral part of the larger machinery.
To break down our food, to regulate sugar, to ward off the toxins of the outside world, our bodies depend onorgans to ensure survival.But, which organ is the biggest? How about the smallest? Can you live without some of your organs?
Take a deeper look inside your own anatomy with the answers to these questions,plus a few bonus facts about your bones and muscles, organs' helpful counterparts.
Organ transplant milestone:As US crosses 1 million mark, advances offer hope for millions more
Organs from the animal world: First-ever pig-to-human heart transplant offers hope for thousands in need of organs
The skin is the largest organ in the body. It is an external rather than an internal organ.
According to National Geographic, the average adult carries around 8 pounds and 22 square feet of skin on their body.
Yes, the skin is an organ, the largest.
It can seem counterintuitive since many of our other organs are unseen. The skin,made up of three layers: the Epidermis, the Dermisand the Hypodermis, is an external organ. It serves as a very important barrier between the body and bacteria, chemicals, and temperature.
Treat your skin right: Want smooth, glowing skin all over? Add these body products into your routine
Healthline reports thatthe top five largest organs in the human body are:
The liver is the bodys largest solid, internal organ. In the upper right part of your abdomen, the liver is your body's filtration system.
It filters toxins out of the blood and produces protein for blood plasma. The liver also produces bile, a product which helps to move waste and break down fats in the small intestine during digestion.
It is a dark brown/red and weighs in at approximately 3 pounds.
To date, there are 79 generally recognized organs in the human body, both internal and external.
This is not a question with a direct answer, as strength has many different measures.
Based on weight, the Library of Congress reports that the strongest muscle in the body is the Masseter. It is one of the four muscles responsible for chewing.
The largest muscle in the human body is the Gluteus Maximus. It is responsible for keeping your posture upright, and is the principal antigravity force working when you walk up stairs.
Other strong muscles include the tongue, heart, uterine muscles, external eye muscles, and Soleus(a muscle found just below the calf).
Get your muscles right: Workouts for each fitness goal, from weight loss to finding your abs
The femur.
It is the longest and strongest bone in your body. The femur is your thigh bone, running from your knee to your hip. Its a difficult bone to break, but if you do, youll likely need surgery.
The pineal gland. It is an incredibly small endocrine gland found in the brain that regulates your circadian rhythm (sleep pattern) by releasing melatonin.
This ever so small organ is shaped like a tiny pinecone, hence the name pine-al gland.
There are 8 blood types, made from four different blood groups A, B, AB, and O. Your genetic makeup determines which blood group you will fall into.
Each of these letters or letter combos can be either RhD positive or negative, making the 8 total types:
What is the most common blood type?: Here's which of the eight is most (and least) common.
It may spark some confusionthat arteries, though a category unto themselves, can be organs as well. The arteries are a critical component of the cardiovascular system, pumping oxygenated blood to the rest of your body.
Artery is the specific term used for this type of blood vessel. Organ is a more broad term that is used to describe a group of tissues that structurally form a functioning, specialized unit of the human anatomy.
Since arteries are made up of tissue, and have a specialized function, they can be classified as organs.
Beta-cells are responsible for the production of insulin, and then subsequently storing that insulin and secreting it when needed based on concentration levels of glucose and fatty acids in the body.
The human body can feasibly operate without a number of different organs. According to Insider, that list includes:
Of note, some of these organs can be removed without much modification while others require regular medical treatments or adjustments to make a healthy life in their absence feasible.
Just Curious?: Your everyday questions, answered.
Continued here:
What is the largest organ in the body? Skin versus liver, explained. - USA TODAY
Ambry Genetics Publishes 43000 Patient Study Showing Combined RNA and DNA Analysis Identifies Patients Who Are High-Risk for Cancer but Would Have…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical diagnostic testing and a subsidiary of REALM IDx, Inc., announced today the findings of a study that showed paired RNA and DNA genetic testing, conducted at the same time, detected elusive pathogenic variants in 1 of every 950 patients that were missed by DNA testing alone. The findings, published in npj Genomic Medicine, highlight the importance of combining RNA and DNA analysis in hereditary cancer testing to give clinicians and their patients the most accurate and comprehensive genetic data needed to inform patient care and achieve the best outcomes.
According to the National Library of Medicine, as of August 2017, there were approximately 75,000 genetic tests on the market, representing 10,000 unique test types. Unfortunately, many of these DNA-only tests exclude large portions of DNA such as introns, a sequence of DNA that is spliced out before an RNA molecule is translated into a protein. In addition to omitting large portions of introns, DNA-only testing lacks the functional context to determine whether a variant increases cancer risk, which can lead to inconclusive results. These limitations may prevent patients and their families from getting accurate results to inform their preventative or therapeutic care.
Concurrent RNA and DNA testing helps identify more patients at risk by determining if an uncertain result from DNA testing is normal or disease-causing, and expands the range of genetic testing to identify mutations that DNA-only testing misses.
With our +RNAinsight test we were the first company to offer upfront paired DNA and RNA sequencing to give clinicians and their patients the most accurate and comprehensive information about their cancer risk, said Tom Schoenherr, CEO, Ambry Genetics. This study confirms that conducting RNA and DNA testing together is critical to help identify high-risk individuals who would have been missed by DNA-only testing.
Previously, published evidence of the value of RNA sequencing has been limited by studies with small sample sizes and enriched cohorts. This study by Ambry is the largest to examine the impact of paired DNA and RNA analysis in hereditary cancer testing. In the study, tests from 43,524 patients who underwent paired DNA-RNA genetic testing using Ambrys +RNAinsight from March 2019 through April 2020 were examined to determine if the paired sequencing detected more pathogenic variants than DNA testing alone. The analysis identified patients who had disease-causing alterations that DNA testing alone would have misinterpreted. Examining the RNA data resolved variant findings in 549 patients (1 in 79 patients) by providing the required functional data for more accurate interpretation of splicing variants. In addition, the analysis showed that 1 of every 950 patients had a pathogenic deep intronic variant that would not have appeared in DNA testing alone.
The results from the study may underestimate the total clinical impact because some of the patients families who are now eligible for genetic testing were not tested. In addition, the ripple effect created by these updated results extends to past and future patients. These downstream benefits were not quantified in the current study.
This is the largest study of its kind to show the importance of RNA testing in predicting cancer risk, said Carrie Horton, senior clinical research specialist for oncology and first author of the study. Its clear that RNA analysis has the potential to become a standard practice for genetic testing to improve hereditary cancer care.
A webinar, open to the media, genetic counselors, clinicians and other interested parties, will be conducted on Thursday, September 15 at 10 a.m. PT to review the study findings. Registration information is here.
Ambrys +RNAinsight was the first test to provide comprehensive gene coverage for RNA analysis to help classify and detect DNA variants associated with a variety of cancers including breast, ovarian, prostate, colon, pancreatic and uterine. +RNAinsight enables more accurate identification of patients with increased genetic risks for cancer, finds actionable results that may otherwise be missed and decreases the frequency of inconclusive results.
About Ambry Genetics
Ambry Genetics, a subsidiary of REALM IDx, Inc., translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.
Follow this link:
Ambry Genetics Publishes 43000 Patient Study Showing Combined RNA and DNA Analysis Identifies Patients Who Are High-Risk for Cancer but Would Have...
Earths Largest Rodents Were Smaller Than We Once Thought – The New York Times
Modern rodents range in size from pygmy mice weighing less than an ounce to stocky capybaras pushing 175 pounds. But even the largest capybara is a pipsqueak compared with some prehistoric rodents that resembled a cross between a supersized capybara and a hairy hippopotamus. Paleontologists estimate that one, Phoberomys pattersoni, may have weighed as much as 1,300 pounds. Another, Josephoartigasia monesi, was believed to be around 2,000 pounds, as big as a bison.
But these size predictions have long sparked debate. People have said theyre the size of bison, but no one had any methods that could confidently nail down these sizes, said Russell Engelman, a paleontologist pursuing his Ph.D. from Case Western Reserve University.
So Mr. Engelman proposed a new method for accurately describing the dimensions of these rodents of unusual size. In a study published Wednesday in the journal Royal Society Open Science, he downsized the animals by comparing a joint at the back of the skulls of Phoberomys, Josephoartigasia and other prehistoric rodents with those in large modern mammals instead of their pint-size relatives.
Between two million and eight million years ago, giant rodents like Phoberomys and Josephoartigasia inhabited South Americas wetlands. According to Ernesto Blanco, a paleontologist at Universidad de la Repblica in Uruguay who discovered the Josephoartigasia skull in 2008, these giant rodents had a powerful bite that could generate three times as much force as a modern tiger bite, potentially protecting them from predators like terror birds and saber-toothed marsupials.
Much of our understanding of these rodents is tied to their size. Body size is a key trait in mammals because everything you cannot physically measure in the fossil like ecology and physiology is correlated with body size, said Virginie Millien, a zoologist at McGill University who studies the body sizes of rodents and was not involved in the new study. In 2010, Dr. Millien used fossilized femurs to estimate that Phoberomys was the size of a large antelope.
Accurately sizing these gargantuan rodents has proved difficult. One reason is a lack of fossils. While paleontologists have unearthed leg bones and other bits of Phoberomyss skeleton, Josephoartigasia is known from only a single skull. Without fossil evidence, researchers often rely on the anatomies of an extinct animals closest living relatives. However, traits like Josephoartigasias prolonged skull and Phoberomyss bulky femurs are not found in living rodents. Thus, simply increasing the size of a capybara fails to render accurate anatomical estimates, and can yield distorted sizes similar to those seen in a carnival mirror.
So Mr. Engelman turned to the occipital condyle, the joint that helps connect an animals skull with its spine. The size of this joint varies little across all mammals to ensure the skull and spine stay securely attached, making it a bellwether for comparing different species. Usually paleontologists look for traits that are different between animals, Mr. Engelman said, but when youre looking at body size, you want to nail down the parts that have changed the least.
Recently, Mr. Engelman measured the width of the joint in more than 400 species of mammals, including mice and African elephants. He discovered that the occipital condyle width was an accurate predictor of their dimensions. Because the width of these joints was similar across mammals of a particular size, he could compare the size of the prehistoric rodents joints with those of other large mammals without having to extrapolate.
This left Mr. Engelman with drastically decreased sizes: Phoberomys maxed out under 450 pounds, and Josephoartigasia weighed around 1,000 pounds much closer to the size of a pony than a bison. If I made every reasonable assumption I could to make the masses higher, I still couldnt make them as big as people were saying, Mr. Engelman said. Even unreasonable assumptions couldnt get them that big.
Mr. Engelman also believes that this decrease in brawn may boost these rodents brains, which are measly for their perceived size. They have small brains, but they may not have these ridiculously tiny brains that people think they had, he said.
Dr. Blanco believes these figures are more realistic than previous estimates of these rodents weighing a metric ton. But he believes more fossil evidence is required before it is certain how large the largest rodents grew. Even with this excellent method, well have significant uncertainties until we have more than a skull, he said.
While the new findings are less eye-popping than earlier estimates, Dr. Millien said 1,000 pounds is still a really big rat.
Link:
Earths Largest Rodents Were Smaller Than We Once Thought - The New York Times
3D Cell Culture Market to Reach USD 1846 million in 2024 Size, Share, Growth, Emerging Trends, Top 10 Players and Industry Outlook – Digital Journal
Key players in 3D Cell Culture Market are Thermo Fisher Scientific (US), Corning Incorporated (US), Merck KGaA (Germany), Lonza AG (Switzerland), REPROCELL Incorporated (Japan), TissUse (Germany), InSphero (Switzerland), Synthecon (US), 3D Biotek (US), CN Bio (UK), Hamilton Company (US), MIMETAS (Netherlands), Emulate (US).
3D Cell Culture Market Research Report Gives in Detailed Analysis of Industry Segments, Opportunities, Growth and Size.
The global 3D cell culture market size is projected to reach USD 1,846 million in 2024 from USD 892 million in 2019, at a CAGR of 15.7%. The growth of this market is driven mainly by the increasing focus on developing alternatives to animal testing, growing focus on personalized medicine, increasing incidence of chronic diseases, and the availability of funding for research. On the other hand, the lack of infrastructure for 3D cell-based research and the high cost of cell biology research are expected to restrain the growth of this market during the forecast period.
The study involved four major activities in estimating the current size of the global 3D cell culture market. Exhaustive secondary research was done to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing values with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=191072847
The scaffold-based 3D cell cultures segment accounted for the largest share of the 3D cell culture market in 2018
Based on product, the market is segmented into scaffold-based 3D cell cultures, scaffold-free 3D cell cultures, microfluidics-based 3D cell cultures, and magnetic & bioprinted 3D cell cultures. Scaffold-based 3D cell cultures accounted for the largest share of the market in 2018. The advantages of scaffolds in 3D cell culture, such as structural rigidity and the availability of attachment points, have greatly driven the preference for scaffold-based 3D cell cultures and ensured the large share of this segment.
The pharmaceutical & biotechnology companies segment accounted for the largest share of the end-user market in 2018
Based on end user, the market is segmented into pharmaceutical & biotechnology companies, research institutes, the cosmetics industry, and other end users. Pharmaceutical & biotechnology companies accounted for the largest share of the market in 2018. The presence of a large number of pharmaceutical & biotechnology companies, an increase in R&D spending in these companies, and the growing preference for alternative testing models over animal techniques are the key market drivers in this end-user segment.
Market Size Estimation:Both top-down and bottom-up approaches were used to estimate and validate the total size of the global 3D cell culture market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
North America commanded the largest share of the market due to the increasing incidence of cancer and the presence of a well-established pharmaceutical & biotechnology industry. However, the market in Europe is expected to grow at the highest CAGR during the forecast period. The growth of the market in Europe is attributed to the growth of its pharmaceutical and biotechnology industry, recent commercialization ofmicrofluidics-based products, the increasing presence of major market players, and a large number of research activities conducted in the region.
Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=191072847
Thermo Fisher Scientific (US), Corning Incorporated (US), Merck KGaA (Germany), Lonza AG (Switzerland), REPROCELL Incorporated (Japan), TissUse (Germany), InSphero (Switzerland), Synthecon (US), 3D Biotek (US), CN Bio (UK), Hamilton Company (US), MIMETAS (Netherlands), Emulate (US), Hrel Corporation (US), QGel SA (Switzerland), SynVivo (US), Advanced BioMatrix (US), Greiner Bio-One International (Austria), and PromoCell (Germany).
Media ContactCompany Name: MarketsandMarketsContact Person: Mr. Aashish MehraEmail: Send EmailPhone: 18886006441Address:630 Dundee Road Suite 430City: NorthbrookState: IL 60062Country: United StatesWebsite: https://www.marketsandmarkets.com/Market-Reports/3d-cell-culture-market-191072847.html
Originally posted here:
3D Cell Culture Market to Reach USD 1846 million in 2024 Size, Share, Growth, Emerging Trends, Top 10 Players and Industry Outlook - Digital Journal
Pandemic worriers shown to have impaired general cognitive abilities – McGill Newsroom
The impairments observed may explain poor decisions about COVID-prevention measures
The COVID-19 pandemic has tested our psychological limits. Some have been more affected than others by the stress of potential illness and the confusion of constantly changing health information and new restrictions. A new study finds the pandemic may have also impaired peoples cognitive abilities and altered risk perception, at a time when making the right health choices is critically important.
Scientists at McGill University and The Neuro (Montreal Neurological Institute-Hospital) surveyed more than 1,500 Americans online from April to June, 2020. Participants were asked to rate their level of worry about the COVID-19 pandemic and complete a battery of psychological tests to measure their basic cognitive abilities like processing and maintaining information in mind. The data were then compared to results of the same tests collected before the pandemic.
For example, participants completed an information processing test where they were asked to match pairs of digits and symbols according to a fixed rule. Participants risk attitudes were measured using an economic decision task where they made a series of hypothetical choices between a certain option (e.g., a sure win of $75), and a risky option (e.g. a 25 per cent chance of winning $0 and a 75 per cent chance of winning $100).
The researchers found that those who experienced more pandemic-related worry had reduced information processing speed, ability to retain information needed to perform tasks, and heightened sensitivity to the odds they were given when taking risks. The pandemic group performed more poorly on the simple cognitive tasks than the pre-pandemic group. Also, participants in the last wave of data collection showed slower processing speed, lower ability to maintain goals in mind, and were more sensitive to risk than those in the first wave.
Interestingly, the study found that pandemic worry predicted individuals tendency to distort described risk levels: underweighting likely probabilities and overweighting unlikely probabilities. This suggests that worry related to COVID may have affected peoples decision-making style, which is crucial as it may influence peoples decisions about getting a COVID-19 vaccine.
The basic cognitive abilities measured here are crucial for healthy daily living and decision-making, says Kevin da Silva Castanheira, a graduate student in McGills Department of Psychology and the studys first author. The impairments associated with worry observed here suggest that under periods of high stress, like a global pandemic, our ability to think, plan, an evaluate risks is altered. Understanding these changes are critical as managing stressful situations often relies on these abilities.
The impact of stress and of worry on cognitive function are well known, but are typically studied in the laboratory setting, says Dr. Madeleine Sharp, a researcher and neurologist at The Neuro and study author. Here, were able to extend these findings by studying the effects of a real-world stressor in a large sample. An important future direction will be to examine why some people are more sensitive than others to stress and to identify coping strategies that help to protect from the effects of stress.
This study, published in the open access journal PLOS ONE, was funded with the help of a Canada Discovery Grant from the Natural Sciences and Engineering Research Council, the Social Sciences and Humanities Research Council of Canada, the Canada Foundation for Innovation, Fonds de Recherche du Qubec Sant, and the G. W. Stairs Fund.
The Neuro
The Neuro The Montreal Neurological Institute-Hospital is a bilingual, world-leading destination for brain research and advanced patient care. Since its founding in 1934 by renowned neurosurgeon Dr. Wilder Penfield, The Neuro has grown to be the largest specialized neuroscience research and clinical center in Canada, and one of the largest in the world. The seamless integration of research, patient care, and training of the worlds top minds make The Neuro uniquely positioned to have a significant impact on the understanding and treatment of nervous system disorders. In 2016, The Neuro became the first institute in the world to fully embrace the Open Science philosophy, creating the Tanenbaum Open Science Institute. The Montreal Neurological Institute is a McGill University research and teaching institute. The Montreal Neurological Hospital is part of the Neuroscience Mission of the McGill University Health Centre.
See the original post:
Pandemic worriers shown to have impaired general cognitive abilities - McGill Newsroom
Dasa expands partnership with SOPHiA GENETICS for the first decentralized cancer biomarker detection solution in Latin America – PRNewswire
SO PAULO, Brazil and BOSTON, Aug. 24, 2021 /PRNewswire/ -- Dasa, the largest integrated healthcare network in Brazil, has chosen to expand upon its partnership with SOPHiA GENETICS SA (Nasdaq: SOPH) to offer the first decentralized HRD (Homologous recombination deficiency) analytics solution in Latin America. HRD is a complex biomarker, important for PARP inhibitors, that helps identify whether cancer patients may respond better to specific treatments, and its use could ultimately lead to personalized therapies that benefit the individual patient.
Renowned in Brazil and abroad, Dasa serves more than 20 million patients per year including approximately 10% of the Brazilian population - through its more than 250,000 medical partners comprised of more than 59 diagnostic medicine brands and hospitals. With the help of the knowledge pooling SOPHiA DDMTM platform, Dasa has drawn further insights upon the many complex molecular datasets that they analyze for the benefit of their patients.
Today's announcement further builds on the partnership that began between the two companies in 2016, when Dasa chose SOPHiA GENETICS to build the original workflow for its genomics lab. This partnership further evolved when Dasa implemented SOPHiA DDMTMRadiomics and Trial Match solutions in 2020 to create the first multimodal approach in the region.For half a decade, the two companies have pioneered new ways to enable scalability and high output screening on complex assays, shortening the path from research to consumer applications and more.
"SOPHiA GENETICS' decentralized approach gives us automated and reproducible results in-house. Their expert bioinformatics team got us up and running on our own, helping us save considerable time, gain efficiency, and offer a more affordable solution for patients," said Gustavo Riedel, Business Director for Genomics and LATAM Clinical Research at Dasa.
"Dasa initially wanted to be able to track the entire diagnostic journey for their cancer patients. With such a large regional network, this is a task that's not unlike navigating an ocean of data through a hurricane. Through our past collaborations and now the addition of our decentralized HRD solution - SOPHiA GENETICS is able to act as the lighthouse that guides Dasa through the storm as they make new discoveries, helping both short and long-term patient care," said Jurgi Camblong, Co-founder and CEO of SOPHiA GENETICS.
To learn more about how SOPHiA GENETICS data-driven insights are improving diagnosis, treatment and drug development for patients and the larger medical community, visit sophiagenetics.com.
About SOPHiA GENETICS:SOPHiA GENETICS is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory, and biopharma institutions globally.
More info:SOPHiAGENETICS.COM; follow@SOPHiAGENETICSon Twitter
About Dasa:Dasa is the largest integrated healthcare network in Brazil, serving more than 20 million people a year, with high technology, intuitive experience and an attitude ahead of time. With more than 40 thousand employees and 250 thousand partner doctors, Dasa is the healthcare solution that people want and that the world needs, being present at every stage of care.
Dasa believes that in order to take care, it is always necessary to take care fully. Therefore, it looks at health management in a preventive, predictive and personalized way. It integrates diagnostic medicine, hospitals, genomics, oncology, care coordination, emergency care, telemedicine, clinical research and science. In all, it has 15 reference hospitals (considering its own network, inorganic growth and deals that are still under regulatory approval), and more than 59 brands including diagnostic medicine and hospitals, distributed in more than 900 units in Brazil.
Dasa guarantees agile, uncomplicated and friction-free navigation of the health journey, for both patients and physicians through its management platform, Nav. In addition, it offers integrated and innovative corporate health solutions through Dasa Empresas. We are Dasa and we are for life. For more information, access: http://www.dasa.com.br.
Contact: [emailprotected]
SOURCE SOPHiA GENETICS
Continue reading here:
Dasa expands partnership with SOPHiA GENETICS for the first decentralized cancer biomarker detection solution in Latin America - PRNewswire
Explore the Cell Expansion Market: Ethical Concerns Regarding Research in Cell Biology – WhaTech
The Global Cell Expansion Market size is estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%. Cell Expansion Market by Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer & Cell-based Research), End-User, and Region - Global Forecast to 2025
The Cell Expansion Market size is estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%.
Growth in this market is primarily driven by the increasing incidence of chronic diseases, government investments for cell-based research, growing focus on personalized medicine, increasing focus on R&D for cell-based therapies, and increasing GMP certifications for cell therapy production facilities.
The media segment accounted for the largest share of the consumables segment in the cell expansion market
Based on product type, consumables are segmented into media, reagents, sera, and disposables. The media segment accounted for the largest share of the consumables segment in the cell expansion market.
The large share of this segment can be attributed to its high requirement during the production of pharmaceutical products and rising R&D investments on cell-based therapies.
Download a PDF Brochure @ http://www.marketsandmarkets.com/pdfdown=194978883
Biotechnology & biopharmaceutical companies accounted for the fastest-growing end user segment of the cell expansion market
Based on end-users, the cell expansion industry market has been segmented into research institutes, biotechnology & biopharmaceutical companies, cell banks, and other end users (includes hospitals, diagnostic centers, and laboratories). In 2019, biotechnology & biopharmaceutical companies were the largest end-users in the cell expansion market, and the trend is the same throughout the forecast period.
North America accounted for the largest share of the cell expansion market
North America accounted for the largest share of the cell expansion industry market.
The large share of this segment can primarily be attributed to the rising incidence of cancer, increasing government funding, rising research activates on stem cell therapies, growing awareness regarding advanced treatment methods, increasing geriatric population, and the strong presence of industry players in the region.
Request a Sample Pages @ http://www.marketsandmarkets.com/request=194978883
Leading Companies
Thermo Fisher Scientific, Inc. (US), Danaher (US), Becton, Dickinson and Company (US), Lonza (Switzerland), Corning, Inc. (US), Merck KGaA (Germany), Sartorius Stedim Biotech (France), Getinge AB (Sweden) Terumo Corporation (Japan), and Miltenyi Biotec (Germany)
This email address is being protected from spambots. You need JavaScript enabled to view it.
See the rest here:
Explore the Cell Expansion Market: Ethical Concerns Regarding Research in Cell Biology - WhaTech
Paw Print Genetics Launches 46 New Tests for Inherited Diseases and Traits Found in Canines – PRNewswire
SPOKANE, Wash., Feb. 1, 2021 /PRNewswire/ --Paw Print Genetics, a division of Genetic Veterinary Sciences, Inc., has launched 46 new, highly desired disease and trait tests to their ever-growing menu of genetic assays. This menu now consists of nearly 300 different tests for over 350 different breeds of dog, the largest in the industry.
Among these are new tests for Labrador retrievers, Beagles, Collies and many other breeds. All tests offered at Paw Print Genetics are based on the published, medical literature, and developed and validated in their laboratory in Spokane, WA.
"We are very excited to provide these tests to our customer community of breeders, veterinarians and dog owners." stated Dr. Lisa Shaffer, CEO of Paw Print Genetics. "By offering the largest menu of tests available, Paw Print Genetics continues to be the leading provider of testing for genetic conditions in dogs. With our staff of geneticists and veterinarians, we provide genetic counseling services to fully support our customers in their testing."
These additional tests further Paw Print Genetics' mission to help breeders achieve optimal canine genetic health. Paw Print Genetics strictly follows the published standards and guidelines for canine clinical genetic testing laboratories.As such, all testing conducted by Paw Print Genetics is performed in duplicate with two independent methods, ensuring a 99.9% accuracy rate.
Learn more about these new test offerings here: https://www.pawprintgenetics.com/blog/2021/01/28/paw-print-genetics-launches-46-new-tests-dogs/
About Paw Print Genetics
Located in Spokane, Washington, Paw Print Genetics was founded in 2012 and is dedicated to raising the standard in canine genetic diagnostic testing, carrier screening, and customer support. Paw Print Genetics' mission is to achieve optimal canine genetic health by providing outstanding resources for dog owners, breeders, trainers, and veterinarians for pets, show dogs and working dogs. For more information, visit https://www.pawprintgenetics.com/
For more information regarding this topic, please contact Jessica Pieros at [emailprotected].
Contact: Jessica Pieros 509-483-5950 [emailprotected]
SOURCE Paw Print Genetics
View original post here:
Paw Print Genetics Launches 46 New Tests for Inherited Diseases and Traits Found in Canines - PRNewswire